Loading...

BIAF BIOAFFINITY TECHNOLOGIES INC Capital Structure Changes 8-K Filing

BFFN

BF

BIOAFFINITY TECHNOLOGIES INC

(BIAF)

2025 8-K

Sales Growth Report

Presentation Materials Rele...

Virtual Roundtable Announce...

Clinical Case Study

Financial Update

Clinical Study Announcement

Press Release Announcement

New Lung Cancer Study

Clinical Case Study

New Clinical Study

Presentation Materials

New Advisory Board

Annual Meeting Notice

Accreditation Success

Management Change

Special Meeting Adjourned

Lung Cancer Presentation

Financial Results Released

Growth Announcement

Patent Approval

Research Presentation

Patent Approval Received

Nasdaq Compliance Update

Stock Offering Update

Stock Split Announcement

Presentation Announcement

CyPath Lung Highlighted

Warrant Price Amendment

Private Placement Funding

Financial Update

Delisting Warning

New Product Launches

New Product Launches

Other Special Situation

Other Special Situation

Failure to Meet Listing Sta...

Equity Offerings

Financial Statements

Equity Offerings

Financial Results

Cost Savings Plan

Warrant Agreement

CEO Salary Increase

Stockholder Votes

Investor Webinar

Quarterly Results

Securities Offering

Management Change

Stockholder Vote

Warrant Inducement Agreement

Financial Results

Annual Meeting Results

Financial Results

Financial Results

Issuance of Shares and Warr...

Securities Purchase Agreement

Financial Results

Management Incentive Bonus ...

New Director Appointment

Approval for Payment of CyP...

Financial Results

Amendment Filing

Presentations to Investors

Amendment to Warrants and A...

Financial Results

Amendment to Employment Agr...

Annual Meeting Results

Financial Results Press Rel...

Appointment of CFO

Presentation at Symposium

Nasdaq Closing Bell Ceremony

External Links:

On September 2, 2025, bioAffinity Technologies, Inc. amended the exercise price for two sets of warrants, increasing the Floor Price from $0.10 to $0.15, reducing the shares issuable from 53,377,497 to 35,584,997 for the May 2025 Warrants, with the August 2025 Warrants pending shareholder approval.

AI Assistant

BIOAFFINITY TECHNOLOGIES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.